Impact of Plasma Alpha-1-acid Glycoprotein Variability on Free Lopinavir Levels

血浆 α-1-酸性糖蛋白变异对游离洛匹那韦水平的影响

• 批准号: 7617890
• 负责人: Ighovwerha Ofotokun
• 金额: $ 12.8万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-06-15 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7617890
• 关键词: AIDS clinical trial group; Accounting; Acids; Acute-Phase Proteins; Adherence; Affinity; Anti-Retroviral Agents; Antiviral Agents; Antiviral Response; Binding; CD4 Lymphocyte Count; CD4 Positive T Lymphocytes; Cell Count; Cells; Chi-Square Tests; Childhood; Clinical; Clinical Pharmacology; Clinical Research; Clinical Trials; Commit; Complex; Computer software; Concentration measurement; Confidence Intervals; Data; Development Plans; Dose; Drug Kinetics; Drug Monitoring; Ensure; Ethics; Exhibits; FDA approved; Fellowship; Fostering; Generations; Glycoproteins; Goals; HIV; HIV-1; Hand; Highly Active Antiretroviral Therapy; Immune; In Vitro; Individual; Inflammation; Inhibitory Concentration 50; Institution; Linear Models; Link; Literature; Lopinavir; Measurement; Measures; Mediating; Mentors; Methods; Metric; Modeling; Multi-Drug Resistance; Odds Ratio; Orosomucoid; Outcome; Participant; Patients; Pharmaceutical Preparations; Pharmacodynamics; Pharmacology; Pharmacotherapy; Phase; Plasma; Plasma Proteins; Predisposition; Probability; Protease Inhibitor; Protein Binding; Proteins; RNA; Reporting; Research; Research Design; Research Methodology; Residual state; Safety; Severity of illness; Shapes; Side; Sigmoid colon; Simulate; Source; Spearman Rank Correlation Coefficient; Study Subject; Testing; Therapeutic; Time; Toxic effect; Training; Treatment Failure; Variant; Viral; Virus; Weight; antiretroviral therapy; base; career; career development; chemotherapeutic agent; cohort; design; drug development; experience; falls; fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether; hazard; in vivo; internal control; medication compliance; oncology; pharmacokinetic model; pregnant; programs; reconstitution; response; restoration; viral resistance

DESCRIPTION (provided by applicant): This proposal is an integrated career development plan that includes training in clinical and antiretroviral (ARV) pharmacokinetic (PK) research methods. The goal is to enable the candidate to establish an independent research career focused on ARV clinical pharmacology. The didactic training component will expand on the MSc in Clinical Research program and the AIDS Clinical Trials Group training fellowship which the candidate recently completed. The candidate's mentors have been involved in mentoring the candidate over the past two years and are committed to fostering his career development. The chief clinical conundrum of ARV therapy is that toxicity is often due to higher circulating drug concentrations, while viral resistance and treatment failure are related to inadequate ARV exposure. The plasma free fraction of ARV is inversely related to protein binding. Protease inhibitors (PI) are bound primarily to cc-1-acid glycoprotein (AAG), an acute phase protein whose plasma levels vary with HIV disease severity and in the setting of inflammation. As a result of this variability, and because of the high binding affinity and low saturation capacity of AAG, this protein has been shown to modulate the disposition and the therapeutic outcomes of chemotherapeutics agents used in oncology. It is therefore conceivable that changes in AAG levels could have similar effects on the PK and pharmacodynamic (PD) of the PIs. We hypothesize that plasma AAG levels in ARV-treated HIV-infected subjects decrease over time due to virologic suppression and immune reconstitution; and that changes in plasma AAG levels are inversely correlated with free concentrations of lopinavir (LPV). Changes in plasma AAG levels over time following institution of LPV/r based therapy will be measured, and correlated with changes in free LPV PK profile from baseline to week-16. Plasma AAG and LPV free levels will be measured by a fixed-time nephelometric method and HPLC-MS/MS respectively. The mean changes in AAG level from baseline to week-16 will be estimated and compared overtime using repeated-measures analyses. The correlation between week-16 changes in AAG levels and week-16 changes in free LPV PK profile following ARV therapy will be evaluated using a Pearson product moment correlation coefficient and the Spearman rank correlation coefficient. Since the free fraction of drug in plasma more accurately reflects the drug available to the target cell, and as a result its PD activities, the finding of an inverse relationship between plasma AAG levels and free LPV concentrations could have important implication in HIV pharmacotherapy.

描述（由申请人提供）：该提案是一个综合的职业发展计划，包括临床和抗逆转录病毒（ARV）药代动力学（PK）研究方法的培训。目标是使候选人能够建立一个专注于ARV临床药理学的独立研究生涯。教学培训部分将在候选人最近完成的临床研究硕士课程和艾滋病临床试验小组培训奖学金的基础上进行扩展。候选人的导师在过去两年中一直参与指导候选人，并致力于促进他的职业发展。ARV治疗的主要临床难题是毒性通常是由于较高的循环药物浓度，而病毒耐药性和治疗失败与ARV暴露不足有关。血浆中ARV游离浓度与蛋白质结合呈负相关。蛋白酶抑制剂（PI）主要与cc-1-酸性糖蛋白（AAG）结合，AAG是一种急性期蛋白，其血浆水平随HIV疾病严重程度和炎症情况而变化。由于这种可变性，并且由于AAG的高结合亲和力和低饱和容量，该蛋白已被证明可以调节肿瘤中使用的化疗药物的处置和治疗结果。因此可以想象，AAG水平的变化可能对pi的PK和药效学（PD）有类似的影响。我们假设arv治疗的hiv感染者血浆AAG水平随着时间的推移由于病毒学抑制和免疫重建而降低；血浆AAG水平的变化与洛匹那韦（LPV）的游离浓度呈负相关。在LPV/r为基础的治疗后，血浆AAG水平随时间的变化将被测量，并与从基线到第16周的游离LPV PK谱的变化相关。血浆AAG和LPV游离水平分别采用固定时间浊度法和HPLC-MS/MS测定。从基线到第16周，AAG水平的平均变化将使用重复测量分析进行估计和比较。ARV治疗后第16周AAG水平变化与第16周游离LPV PK谱变化之间的相关性将采用Pearson积差相关系数和Spearman秩相关系数进行评估。由于血浆中药物的游离部分更准确地反映了靶细胞可利用的药物，从而反映了其PD活性，因此发现血浆AAG水平与游离LPV浓度之间的反比关系可能对HIV药物治疗具有重要意义。